CJC-1295 research guide

CJC-1295 in Kress — GHRH Analog Research Guide

CJC-1295 research guide for Kress. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.

Skip to Sourcing Guide Order CJC-1295 →

CJC-1295 in Kress: Sourcing, Purity & Protocols

CJC-1295 won't be found on pharmacy shelves in Kress or anywhere else for that matter — it's a research compound available through a dedicated online market. The practical advantage of this online-only market is that serious vendors are judged entirely by their analytical documentation, giving researchers access to better quality signals than any local market ever offers. Vendors worth sourcing from openly share batch-matched Certificates of Analysis showing HPLC purity analysis, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the specific lot you are purchasing. What follows is a sourcing and quality evaluation guide built specifically around CJC-1295, covering everything a Kress researcher needs before placing a first order.

CJC-1295: What the Research Shows

The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Kress researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.

How to Source CJC-1295 — Vendor Guide

Quality CJC-1295 sourcing begins with a simple filter: does this vendor publish batch-specific COAs proactively? Suppliers that publish proactively are operating transparently. The HPLC purity trace is the most important document in the COA: it should show a dominant main peak representing CJC-1295, with minimal secondary peaks representing impurities — purity should be stated as ≥98%. Positive vendor signals beyond COA quality: documented vendor history spanning multiple years, responsive technical support who understand testing methodology, and temperature-appropriate packaging with desiccant. The powdered lyophilised form of CJC-1295 is always preferable to liquid pre-made solutions — lyophilised powder retains potency for years in frozen storage, while liquid preparations lose activity within weeks.

Order CJC-1295 — ships to Kress
COA-verified · International tracking · Research grade
Order Now →

Handling CJC-1295 Correctly

As a research compound, CJC-1295 has not been through the clinical trial process required for pharmaceutical approval — its safety profile is characterised by preclinical data and restricted human research data. Temperature excursions — even brief warming above recommended storage temperature — can cause partial degradation without visible changes; always maintain cold chain and work with cold-shipped material. The primary quality-related safety risk in CJC-1295 research is bacterial endotoxin from low-quality material — a confirmed endotoxin test result in the lot-matched COA is the direct mitigation for this hazard. Researchers using CJC-1295 alongside other research compounds should examine published studies for potential interaction data before running stacked compound experiments.

Frequently Asked Questions

What purity is required for CJC-1295 research?

CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.

What is CJC-1295?

CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.

What is the difference between CJC-1295 with DAC and without DAC?

CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.

Order CJC-1295 today
COA-verified · International shipping available
Order Now →